Publications by authors named "Valerie Machuron"
Article Synopsis
- - The study assessed the public health impact of COVID-19 on French patients with risk factors, using a Markov model to estimate various outcomes like hospitalizations, deaths, and costs over two years.
- - Results indicated a significant burden with 256 hospitalizations per 1,000 patients in the first month and 382 over two years, along with 37 deaths and 407 cases of long COVID.
- - The findings highlight an urgent need for effective strategies to reduce COVID-19 burden, especially among older and unvaccinated patients, with notable cost implications for healthcare.
Objective: This article describes the Personalized Reimbursement Model (PRM) program methodology, limitations, achievement and perspectives in using real-world data of cancer drugs use to improve and personalize drug pricing and reimbursement in France.
Materials And Methods: PRM platform aggregates Electronic Pharmacy Records (EPR) data from French medical centers (PRM centers) to build retrospective cohorts of patients treated with injectable cancer drugs in a hospital setting. Data extracted on January 1st, 2020, from breast cancer (BC) patients who received trastuzumab, trastuzumab emtansin or pertuzumab since January 1st, 2011, and from lung cancer (LC) patients who received bevacizumab or atezolizumab since January 1st, 2015, enabled recovering their injectable cancer drugs history from diagnosis date until December 30th, 2019, and served as dataset for assessment.